Antibody Information
General Information of This Antibody
| Antibody ID | ANI0GKIYY |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | HzMUC1 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Mucin-1 (MUC1) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
HzMUC1-MMAE [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 33.50% (Day 21) | High MUC1 expression (MUC1+++) | ||
| Method Description |
To examine the efficacy of the HzMUC1-MMAE in decreasing pancreatic tumor growth in vivo,pancreatic tumor xenograft mouse model was established. BALB/c nu/nu mice were subcutaneously injected with CFPAC-1 cells. When the CFPAC-1 tumors reached the sizes of 150 mm3,mice were randomized into two groups and treated with PBS and HzMUC1-MMAE (5 mg/kg,every 6 days,for 2 doses).
Click to Show/Hide
|
||||
| In Vivo Model | Pancreatic cancer CDX model | ||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 83.10% (Day 28) | High MUC1 expression (MUC1+++) | ||
| Method Description |
To examine the efficacy of the HzMUC1-MMAE in decreasing pancreatic tumor growth in vivo,pancreatic tumor xenograft mouse model was established. BALB/c nu/nu mice were subcutaneously injected with Capan-2 cells. When the Capan-2 tumors reached the sizes of 120 mm3,mice were randomized into two groups and treated with PBS and HzMUC1-MMAE (5 mg/kg,every 6 days,for 2 doses).
Click to Show/Hide
|
||||
| In Vivo Model | Pancreatic cancer CDX model | ||||
| In Vitro Model | Pancreatic cancer | Pancreatic cancer cells | Homo sapiens | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
26.00 nM
|
High MUC1 expression (MUC1+++) | ||
| Method Description |
The inhibitory activity of HzMUC1-ADC against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 5 days.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | Capan-2 cells | CVCL_0026 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
50.00 nM
|
High MUC1 expression (MUC1+++) | ||
| Method Description |
The inhibitory activity of HzMUC1-ADC against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 5 days.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | CFPAC-1 cells | CVCL_1119 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
59.00 nM
|
Moderate MUC1 expression (MUC1++) | ||
| Method Description |
The inhibitory activity of HzMUC1-ADC against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 5 days.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | PANC-1 cells | CVCL_0480 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 10.00 uM | Negative MUC1 expression (MUC1-) | ||
| Method Description |
The inhibitory activity of HzMUC1-ADC against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 5 days.
|
||||
| In Vitro Model | Pancreatic adenocarcinoma | SW1990 cells | CVCL_1723 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.